Clin2
NCT05474729Possibly a fitRecruiting

Minocycline for chronic autoimmune eye inflammation

MinocyclineUveitisRetinal Degeneration

Treatments studied

Part of Eyes & vision clinical trials.

This trial tests whether minocycline, an antibiotic that can also reduce inflammation, helps improve chronic autoimmune uveitis and protect vision. It may help by lowering ongoing immune irritation that damages the eye.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1/Phase 2
Enrollment
10 people
Ages
18 years to 70 years
Study type
Interventional

Who can take part

  • You are 18 to 60 years old.
  • You have an autoimmune disease affecting the eyes (autoimmune uveitis) with vision damage.
  • You can sign consent and attend all scheduled study visits.
  • You do not have an allergy to minocycline or other tetracycline antibiotics.
  • Your liver, heart, kidney, and thyroid tests are normal enough for study treatment.
  • You are not taking pregnancy-protecting or ongoing immune medicines like steroids or other immune-suppressing drugs.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06390436Not yet recruiting· Phase 4
Lowering adalimumab dose for chronic eye inflammation

This study tests whether a lower dose of adalimumab (a biologic medication) can keep controlling chronic non-infectious uveitis (eye inflammation that is not caused by an infection) after it has been well-controlled for a long time. If you have stable eye inflammation and have been on the standard adalimumab dose (40 mg every 2 weeks) for at least 24 weeks, this trial may be suitable for you.

Avignon
NCT05592717Recruiting
YUTIQ implant for chronic non-infectious eye inflammation

This trial tests whether a small steroid implant placed inside the eye (YUTIQ 0.18 mg) can control chronic non-infectious uveitis. It may help reduce active inflammation and prevent flare-ups, as long as you’ve had recent signs of active disease and can follow the medication and eye-visit rules.

Tianjin, Tianjin Municipality
NCT05105347Not yet recruiting· Phase 4
Adalimumab plus moderate steroid for difficult Behçet’s eye inflammation

This trial studies whether adalimumab (an immune medicine) added to a medium-dose steroid improves eye inflammation from refractory Behçet’s disease that keeps coming back. It also checks safety to see if the benefits outweigh risks.

NCT07547995Recruiting· Phase 2
A study of a new drug for active uveitis

This study tests a new drug (GenSci048) for people with active, non-infectious uveitis in the middle or back of the eye, who are already taking oral steroids. The goal is to see if the drug can better control inflammation and reduce the need for steroids.

Shanghai, Shanghai Municipality
NCT06273748Recruiting
Study on chronic eye inflammation in children

This study looks at children with long-term eye inflammation that is not caused by an infection. It aims to learn more about the condition and how to better help patients.

Kansas City, Kansas
NCT07082855Not yet recruiting· Phase 3
Minocycline for retinitis pigmentosa

This trial tests whether the antibiotic minocycline can slow vision loss from retinitis pigmentosa. If you are between 18 and 60 and have some remaining sight, this study may help find a new treatment.

Guangzhou, Guangdong

Hear when a new Minocycline trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.